Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2023-188444

Published: 2023

Journal Articles

IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

Keshu Zhou, Yuqin Song, Tienan Yi, Shuling Hou, Xingchen Liu, Ningjing Lin, Tingting Du, Xing Zhao, Xiaobo Wu, Xiwen Zhao, Wei Meng, Wencheng Xu, Qiying Lu, Wenzhi Tian, Jun Zhu

Blood (2023) 142 (Supplement 1): 609.

https://doi.org/10.1182/blood-2023-174829

Published: 2023

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Journal Articles

Combination of CDK4/6 Inhibitor Palbociclib and PI3K Inhibitor Idelalisib Synergistically Induces an Anti-Tumor Effect in B-Cell Lymphoma and Overcomes Ibrutinib Resistance

Dingyao Hu, Jiaowu Cao, Dedao Wang, Jiajin Wu, Lan Mi, Lingyan Ping, Ning Ding, Yuqin Song, Jun Zhu

Blood (2023) 142 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2023-185912

Published: 2023

Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu

Blood (2023) 142 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2023-181352

Published: 2023

Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2023-173645

Published: 2023

Journal Articles

TBI/Ratg-Based Conditioning for Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in 11 Cases of Chemotherapy-Resistant Advanced-Stage Peripheral T-Cell Lymphoma

JUN Zhu, Rong Xu, Chun Wang, Chuxian Zhao, Ying Jiang, Daolin Wei, Shan Shao, Huixia Liu, Su Li

Blood (2023) 142 (Supplement 1): 6981.

https://doi.org/10.1182/blood-2023-174062

Published: 2023

Journal Articles

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma

Ning Ding, Yan Xie, Yong Guo, Kecheng Li, Tingting DU, Zhenjun Li, Yuejiao Li, Jiaowu Cao, Dingyao Hu, Lih-Yun Hsu, Richard Miller, Jun Zhu, Yuqin Song

Blood (2023) 142 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2023-174421

Published: 2023

Journal Articles

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Yuqin Song, Keshu Zhou, Lanfang Li, Aibin Liang, Yun Qin, Zhen Xia, Yongen Gu, Zisong Zhou, Alex Tian, Jun Zhu

Blood (2023) 142 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2023-178430

Published: 2023

Journal Articles

Real-World Effectiveness and Safety of Hetrombopag for Delayed Platelet Engraftment Post-Allogeneic Hematopoietic Stem Cell Transplantation

JUN Zhu, Yun Lou, Chuxian Zhao, Ying Jiang, Daolin Wei, Chun Wang, Shan Shao, Huixia Liu, Su Li

Blood (2023) 142 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2023-178605

Published: 2023

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

Short-Term Substitution of Calcineurin Inhibitors (CNIs) with Recombinant Humanized Anti-CD25 Monoclonal Antibody (anti-CD25 rhMAb) As aGVHD Prophylaxis in Cnis Intolerant Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Shan Shao, Huixia Liu, Ying Jiang, Su Li, Daolin Wei, JUN Zhu, Chun Wang, Chuxian Zhao

Blood (2023) 142 (Supplement 1): 7007.

https://doi.org/10.1182/blood-2023-173673

Published: 2023

Journal Articles

Upfront Autologous Stem Cell Transplant at First Complete Remission in Patients with Advanced-Stage Extra-Nodal NK/T Cell Lymphoma: A Multicenter Retrospective Study

Shaoxuan Hu, Linjun Zhao, Weiping Liu, Wenrong Huang, Shunan Qi, Xiaopei Wang, Yuqin Song, Yexiong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 3597.

https://doi.org/10.1182/blood-2023-184486

Published: 2023

Journal Articles

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Jun Zhu, Yuqin Song, Ye Guo, Keshu Zhou, Wenyu Li, Yu Yang, Qingqing Cai, Zhao Wang, Haiyan Yang

Blood (2023) 142 (Supplement 1): 3089.

https://doi.org/10.1182/blood-2023-189675

Published: 2023

Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2023-180694

Published: 2023

Journal Articles

First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Yuqin Song, Keshu Zhou, Hongmei Jing, Jianqiu Wu, Haiyan Yang, Yu Bai, Ke Fang, Ziyi Liu, Jun Zhu, Chan Y. Cheah

Blood (2023) 142 (Supplement 1): 4465.

https://doi.org/10.1182/blood-2023-185270

Published: 2023

Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood (2023) 142 (Supplement 1): 4458.

https://doi.org/10.1182/blood-2023-181385

Published: 2023

Journal Articles

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2023-180485

Published: 2023

Journal Articles

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Yuqin Song, Shuhua Yi, Haiyan Yang, Ru Feng, Huiqiang Huang, Qingyuan Zhang, Yanyan Liu, Ye Guo, Huilai Zhang, Liling Zhang, Yijiao Qian, JianKun Zhu, Jun Zhu

Blood (2023) 142 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2023-173287

Published: 2023

Journal Articles

Impact of Immunosuppression Intensified Conditioning Regimen for Patients with Strong Positive Pre-Transplantation Donor Specific Anti-HLA Antibodies (DSAs) Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Huixia Liu, Daolin Wei, Shan Shao, Ying Jiang, Su Li, JUN Zhu, Chun Wang, Chuxian Zhao

Blood (2023) 142 (Supplement 1): 6989.

https://doi.org/10.1182/blood-2023-174240

Published: 2023

NARROW

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Combination of CDK4/6 Inhibitor Palbociclib and PI3K Inhibitor Idelalisib Synergistically Induces an Anti-Tumor Effect in B-Cell Lymphoma and Overcomes Ibrutinib Resistance

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

TBI/Ratg-Based Conditioning for Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in 11 Cases of Chemotherapy-Resistant Advanced-Stage Peripheral T-Cell Lymphoma

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Real-World Effectiveness and Safety of Hetrombopag for Delayed Platelet Engraftment Post-Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Short-Term Substitution of Calcineurin Inhibitors (CNIs) with Recombinant Humanized Anti-CD25 Monoclonal Antibody (anti-CD25 rhMAb) As aGVHD Prophylaxis in Cnis Intolerant Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Upfront Autologous Stem Cell Transplant at First Complete Remission in Patients with Advanced-Stage Extra-Nodal NK/T Cell Lymphoma: A Multicenter Retrospective Study

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study

Impact of Immunosuppression Intensified Conditioning Regimen for Patients with Strong Positive Pre-Transplantation Donor Specific Anti-HLA Antibodies (DSAs) Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only